In a world of biotech hype, Anokion's website is a ghost town—just 2,390 monthly visitors and a single Google Font. Yet this Swiss-American company has raised $77.6M to pioneer 'inverse vaccines' that could revolutionize autoimmune treatment. The story isn't in the pixels; it's in the funding, the team, and the audacious science.

"Their website is a ghost town, but their bank account is a fortress. This is biotech operating in stealth mode."

The biotech sector is crowded with companies chasing the same immunology targets, but Anokion's approach to 'inverse vaccines'—training the immune system to tolerate rather than attack—positions them in a rarefied niche. With $77.6M raised against just $3.7M in revenue, they're in the classic capital-intensive R&D phase where every dollar must fuel clinical milestones.

• Inverse vaccine platform targeting autoimmune diseases (multiple sclerosis, type 1 diabetes)
• Swiss-American hybrid structure—global reach with clinical operations
• Pre-revenue model focused on pipeline development and partnership deals
• Lean team of 48 suggests capital efficiency and focused burn rate
• Minimal web presence indicates active stealth mode or regulatory-sensitive positioning